DAXOR CORPORATION - CLOSED END FUND

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

27 سبتمبر 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

19 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management

12 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee

05 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

04 سبتمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

03 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 سبتمبر 2024 12:15:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

29 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer

06 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

05 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer

24 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide

11 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

18 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

16 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

15 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

10 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

01 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

25 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

22 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

18 مارس 2024 14:18:00 بحسب Nasdaq GlobeNewswire